Commercialising a novel diagnostic panel for patient stratification in Age relat...
Commercialising a novel diagnostic panel for patient stratification in Age related MACULAr Degeneration
"In MACULA2 we aim to develop a genetic diagnostic test for complement activation that will allow proper stratification of patients with age-related macular degeneration (AMD). AMD is an inflammatory disease, the #1 cause of blind...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EYE-RISK
Exploring the combined role of genetic and non genetic facto...
6M€
Cerrado
BES-2017-080518
DESARROLLO DE METODOLOGIAS BASADAS EN ESPECTROMETRIA DE MASA...
93K€
Cerrado
PREVENT
Precision medicine approach to rare vascular malformations t...
1M€
Cerrado
inHForm
Integrative omics of heart failure to inform discovery of no...
1M€
Cerrado
SAF2017-88908-R
UNA APROXIMACION DE MEDICINA DE SISTEMAS BASADA EN MODELOS D...
194K€
Cerrado
PTQ-14-06856
Identificación, desarrollo y validación clínica de un sistem...
50K€
Cerrado
Información proyecto MACULA2
Duración del proyecto: 21 meses
Fecha Inicio: 2017-08-02
Fecha Fin: 2019-05-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"In MACULA2 we aim to develop a genetic diagnostic test for complement activation that will allow proper stratification of patients with age-related macular degeneration (AMD). AMD is an inflammatory disease, the #1 cause of blindness in the world, with 196 million patients estimated for 2020. Such a test does not currently exist, strongly hampering drug development and patient treatment. Poor patient stratification contributes to high failure rates in trials for AMD. Local and systemic inflammation in AMD are caused by deregulated activation of the alternative pathway of the complement system. In AMD, some patients have higher complement activation levels compared to controls, which stimulates further inflammation. Several complement-lowering therapies for AMD are under development. Pharmaceutical companies are aware that patients with a genetic predisposition to higher complement activation levels will potentially benefit most from such treatments. Without sound patient stratification, therapies that are currently in clinical trials may not reach the statistical significance needed for approval. However, certain individuals might actually benefit from these therapies because of their specific genetic makeup. We aim to solve the challenge of patient stratification in AMD by developing a novel diagnostic test based on genetic testing combined with a patient questionnaire. An AMD diagnostic test will contribute towards a precision medicine approach towards treatment of patients."